Gastric Adenocarcinoma Metastasis: Incidence and Common Sites
Approximately 40-45% of gastric adenocarcinoma patients present with metastatic disease at diagnosis, with the liver being the most common metastatic site (occurring in 21-48% of metastatic cases), followed by peritoneal metastases (29-43%), distant lymph nodes (9-20%), and lung (7-15%) 1, 2, 3.
Proportion Presenting with Metastatic Disease
The burden of metastatic disease at presentation is substantial. In the largest US-based cohort analysis from the SEER database, 45.79% of gastric cancer patients had metastatic disease at diagnosis 1. This aligns with guideline recognition that gastric cancer generally carries a poor prognosis because it is often diagnosed at an advanced stage 4.
Most Common Metastatic Sites
Overall Metastatic Pattern
The metastatic distribution varies significantly by study population, but consistent patterns emerge:
- Liver metastases: 21-48% of metastatic patients 1, 5, 2, 3
- Peritoneal metastases: 29-43% 2, 6, 3
- Distant lymph nodes: 9-20% 5, 2
- Lung metastases: 7-15% 5, 6, 3
- Bone metastases: 6-12% 1, 6, 3
- Brain metastases: <1% 1
Single-Site vs. Multi-Site Metastases
Among metastatic patients, approximately 46% present with single-site metastasis, while 13% have multi-site metastases 1. The most common single-site metastases are:
- Liver-only: 32.72%
- Bone-only: 6.81%
- Lung-only: 5.46%
- Brain-only: 0.80%
Critical Variations by Tumor Characteristics
Anatomical Location Matters
Proximal (cardia) gastric cancers demonstrate fundamentally different metastatic behavior than distal gastric cancers 5, 3:
Proximal/Cardia Cancers:
- Higher rates of liver metastases (21.4% vs. 11.8%)
- Higher rates of distant lymph node metastases (14.6% vs. 9.5%)
- Higher rates of lung metastases (13% vs. 7%)
- Lower rates of peritoneal metastases (11.9% vs. 19.5%)
Distal/Antral Cancers:
- Peritoneal metastases are the predominant pattern (19.5%)
- Lower hematogenous spread
Histological Type Profoundly Affects Metastatic Pattern
The Lauren classification predicts metastatic organotropism 6:
Intestinal Type (57% of metastatic cases):
- Liver metastases: 57%
- Lung metastases: 13%
- Peritoneal metastases: 29%
Diffuse Type (38% of metastatic cases):
- Peritoneal metastases: 58%
- Liver metastases: 21%
- Bone metastases: 9%
- Lung metastases: 7%
Signet ring cell adenocarcinomas specifically show increased peritoneal (34% vs. 6%), bone, and ovarian metastases, with decreased liver and lung involvement 2, 3.
Prognostic Implications
Median overall survival for metastatic gastric cancer is 3-4 months 1, 3. Survival varies by metastatic site:
- Best prognosis: Isolated distant lymph node metastases (7.6 months median survival) 2
- Worst prognosis: Bone and liver metastases (2 months median survival) 3
- Multi-site metastases confer worse prognosis than single-site (3 vs. 4 months) 1
Diffuse type carcinomas have worse survival regardless of metastatic site or number 6.
Clinical Pitfalls and Surveillance Considerations
Common pitfall: Assuming uniform metastatic patterns across all gastric cancers. The primary tumor location and histological subtype fundamentally alter metastatic organotropism 5, 6.
Surveillance strategy:
- Cardia cancer survivors require heightened surveillance for extraperitoneal metastases (liver, lung, distant nodes)
- Distal/diffuse type cancers warrant particular attention to peritoneal involvement
- Signet ring histology should prompt consideration of bone metastases if symptoms emerge 3
Staging considerations: Laparoscopy with peritoneal washings is recommended in all potentially resectable cases to exclude occult peritoneal metastases, which are frequently missed on imaging 7.